EP3687540A4 - Heteroarylverbindungen als cxcr4-inhibitoren, zusammensetzung und verfahren zur verwendung davon - Google Patents

Heteroarylverbindungen als cxcr4-inhibitoren, zusammensetzung und verfahren zur verwendung davon Download PDF

Info

Publication number
EP3687540A4
EP3687540A4 EP18859565.6A EP18859565A EP3687540A4 EP 3687540 A4 EP3687540 A4 EP 3687540A4 EP 18859565 A EP18859565 A EP 18859565A EP 3687540 A4 EP3687540 A4 EP 3687540A4
Authority
EP
European Patent Office
Prior art keywords
composition
compounds used
heteroaryl compounds
cxcr4 inhibitors
cxcr4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18859565.6A
Other languages
English (en)
French (fr)
Other versions
EP3687540A1 (de
Inventor
Xiaohu Zhang
Jiyue ZHENG
Haikuo MA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cgenetech Suzhou China Co Ltd
Original Assignee
Cgenetech Suzhou China Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201810265417.9A external-priority patent/CN110317191B/zh
Priority claimed from CN201810710340.1A external-priority patent/CN110669036B/zh
Priority claimed from CN201811034891.7A external-priority patent/CN109553604B/zh
Application filed by Cgenetech Suzhou China Co Ltd filed Critical Cgenetech Suzhou China Co Ltd
Publication of EP3687540A1 publication Critical patent/EP3687540A1/de
Publication of EP3687540A4 publication Critical patent/EP3687540A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C07F7/0836—Compounds with one or more Si-OH or Si-O-metal linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP18859565.6A 2017-09-25 2018-09-24 Heteroarylverbindungen als cxcr4-inhibitoren, zusammensetzung und verfahren zur verwendung davon Pending EP3687540A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201710875041 2017-09-25
CN201810265417.9A CN110317191B (zh) 2018-03-28 2018-03-28 一种吡啶杂环化合物及其作为cxcr4抑制剂的应用
CN201810710340.1A CN110669036B (zh) 2018-07-02 2018-07-02 一类具有cxcr4信号通路抑制活性的杂环化合物及其应用
CN201811034891.7A CN109553604B (zh) 2017-09-25 2018-09-05 4-氨基嘧啶衍生物作cxcr4抑制剂及其应用
PCT/US2018/052503 WO2019060860A1 (en) 2017-09-25 2018-09-24 HETEROARYL COMPOUNDS AS INHIBITORS OF CXCR4, COMPOSITION AND METHOD OF USE THEREOF

Publications (2)

Publication Number Publication Date
EP3687540A1 EP3687540A1 (de) 2020-08-05
EP3687540A4 true EP3687540A4 (de) 2021-04-21

Family

ID=65809950

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18859565.6A Pending EP3687540A4 (de) 2017-09-25 2018-09-24 Heteroarylverbindungen als cxcr4-inhibitoren, zusammensetzung und verfahren zur verwendung davon

Country Status (3)

Country Link
EP (1) EP3687540A4 (de)
KR (1) KR102678977B1 (de)
WO (1) WO2019060860A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3585387A4 (de) 2017-02-21 2020-08-12 Emory University Chemokin-cxcr4-rezeptormodulatoren und verwendung damit
US11649235B2 (en) 2018-03-19 2023-05-16 Emory University Pan-tropic entry inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
SMT202500271T1 (it) 2020-07-02 2025-09-12 Incyte Corp Composti di urea triciclici come inibitori di v617f di jak2
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
CN119173514A (zh) 2022-03-17 2024-12-20 因赛特公司 作为jak2 v617f抑制剂的三环脲化合物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023400A2 (en) * 2004-08-16 2006-03-02 Smithkline Beecham Corporation Chemical compounds
WO2006026703A2 (en) * 2004-09-02 2006-03-09 Smithkline Beecham Corporation Chemical compounds
WO2006076131A2 (en) * 2004-12-17 2006-07-20 Smithkline Beecham Corporation Chemical compounds
WO2007027999A2 (en) * 2005-08-31 2007-03-08 Smithkline Beecham Corporation Chemical compounds
CN102675305A (zh) * 2011-03-08 2012-09-19 中国科学院上海药物研究所 一类咪唑并吡啶类化合物及其制备方法和用途
CN103570683A (zh) * 2012-07-30 2014-02-12 中国科学院上海药物研究所 多取代胺类化合物及其制备方法和用途
WO2017223243A1 (en) * 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051387A1 (en) * 2006-06-09 2008-02-28 Yuelian Xu Tetrahydropyrido[3,4-d]pyrimidines and related analogues
AU2009228034A1 (en) * 2008-03-28 2009-10-01 Altiris Therapeutics Chemokine receptor modulators
WO2010025416A1 (en) * 2008-08-29 2010-03-04 Genzyme Corporation Cxcr4 antagonists for kidney injury
WO2017011517A1 (en) * 2015-07-16 2017-01-19 Emory University Bis-amines, compositions, and uses related to cxcr4 inhibition

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023400A2 (en) * 2004-08-16 2006-03-02 Smithkline Beecham Corporation Chemical compounds
WO2006026703A2 (en) * 2004-09-02 2006-03-09 Smithkline Beecham Corporation Chemical compounds
WO2006076131A2 (en) * 2004-12-17 2006-07-20 Smithkline Beecham Corporation Chemical compounds
WO2007027999A2 (en) * 2005-08-31 2007-03-08 Smithkline Beecham Corporation Chemical compounds
CN102675305A (zh) * 2011-03-08 2012-09-19 中国科学院上海药物研究所 一类咪唑并吡啶类化合物及其制备方法和用途
CN103570683A (zh) * 2012-07-30 2014-02-12 中国科学院上海药物研究所 多取代胺类化合物及其制备方法和用途
WO2017223243A1 (en) * 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019060860A1 *

Also Published As

Publication number Publication date
WO2019060860A1 (en) 2019-03-28
KR102678977B1 (ko) 2024-06-28
EP3687540A1 (de) 2020-08-05
KR20200058443A (ko) 2020-05-27

Similar Documents

Publication Publication Date Title
EP3687540A4 (de) Heteroarylverbindungen als cxcr4-inhibitoren, zusammensetzung und verfahren zur verwendung davon
FR24C1009I2 (fr) Composés utilisés comme inhibiteurs de kinase
EP3718572A4 (de) Nukleinsäure, zusammensetzung und konjugat mit nukleinsäure, verfahren zu ihrer herstellung und ihre verwendung
EP3681499A4 (de) Verbindungen als ras-inhibitoren und ihre verwendung
MA47233A (fr) Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation
JOP20250289A1 (ar) صور بلورية جديدة
MA55633A (fr) Salicylamides de spiroheptane et composés associés utilisés comme inhibiteurs de rock
MA56032A (fr) Composés, compositions et procédés d'utilisation
EP3768267A4 (de) Kinaseinhibitorverbindungen und zusammensetzungen und verfahren zur verwendung
MA55695A (fr) Composés chimiques comme inhibiteurs de l'activité interleukine-1
ZA202109003B (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
EP3727401A4 (de) Cyclische di-nukleotid-verbindungen als sting-agonisten
EP3402799A4 (de) Heterocyclische verbindungen als rsv-inhibitoren
EP3807253A4 (de) Cyanochinolinamidverbindungen als her2-inhibitoren und verwendungsverfahren
EP3630962A4 (de) Cblb-endonuklease-varianten, zusammensetzungen und verfahren zur verwendung
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
MA41677A (fr) Composés alpha-cinnamide et compositions comme inhibiteurs de hdac8
EP3337787A4 (de) Pyrazolo-kondensierte heterocyclische verbindungen als erk-inhibitoren
EP2968357A4 (de) S-imino-s-oxo-iminothiazin-verbindungen als bace-hemmer, zusammensetzungen und deren verwendung
BR112017026682A2 (pt) novos compostos bicíclicos como inibidores de dupla ação de atx/ca
EP3964518C0 (de) Cd73-inhibitor, herstellungsverfahren dafür und anwendungen davon
EP3487498A4 (de) Heteroarylverbindungen als inhibitoren von nekrose, zusammensetzung und anwendung davon
EP3302488A4 (de) Neuartige verwendung von arylchinolinderivaten als inhibitoren von gefässbildender mimikry
EP3710006A4 (de) Substituierte heteroarylverbindungen und verfahren zur verwendung
EP3906028A4 (de) Kinaseinhibitorverbindungen und zusammensetzungen und verfahren zur verwendung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200326

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/444 20060101AFI20210208BHEP

Ipc: A61P 11/00 20060101ALI20210208BHEP

Ipc: A61P 35/00 20060101ALI20210208BHEP

Ipc: C07D 401/14 20060101ALI20210208BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20210324

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/444 20060101AFI20210318BHEP

Ipc: C07D 401/14 20060101ALI20210318BHEP

Ipc: A61P 11/00 20060101ALI20210318BHEP

Ipc: A61P 35/00 20060101ALI20210318BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220802